- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2013–2025 · program · P50
Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer
Nancy U Lin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2022 · cooperative agreement · U01
The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center
William C. Hahn · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2024 · program · P50
Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer
Nancy U Lin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2022 · cooperative agreement · U01
The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center
William C. Hahn · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2024 · program · P50
Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer
Nancy U Lin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2023 · cooperative agreement · U01
The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center
William C. Hahn · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2022 · cooperative agreement · U01
The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center
William C. Hahn · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2024 · program · P50
Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer
Eric P Winer · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2030 · program · P50
Dana Farber/Harvard Cancer Center Specialized Program of Research Excellence in Breast Cancer
Leif W Ellisen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2030 · program · P50
Project 4: Combined targeting of DNA repair and macrophage-mediated immunosuppression in BRCA1/2-associated breast cancer
Geoffrey I. Shapiro · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2025 · program · P50
Project 3: Improving therapeutic approaches for breast cancer brain metastases
Jean Zhao · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2030 · program · P50
Development Research Program
Myles A Brown · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2025 · program · P50
Project 4: Combined use of immunotherapy and targeted treatments for triple negative breast cancer
Kornelia Polyak · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2030 · program · P50
Career Enhancement Program
Judy E. Garber · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2025 · program · P50
Project 2: Combination immunotherapy approaches to overcome therapeutic resistance in HER2-positive breast cancer
Ian E Krop · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2020 · program · P01
T:B Collaboration and Induction of Autoimmune Tissue Inflammation
Vijay K. Kuchroo · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2020 · program · P01
Regulation of T cell immunity by stromal cells in autoimmune tissue inflammation
Vijay K. Kuchroo · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2025 · program · P50
Core C: Biospecimen and Pathology
Deborah Dillon · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2025 · program · P50
Core B: Biostatistics and Computational Biology
Meredith M Regan · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2030 · program · P50
Core A: Biospecimen and Pathology
Deborah A. Dillon · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2020 · program · P01
Scientific Leadership and Administrative Coordination of PPG
Vijay K. Kuchroo · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2030 · program · P50
Project 1: Incorporating antibody drug conjugates into mechanism-based combinations to target metastatic breast cancer
Leif W Ellisen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2030 · program · P50
Project 3: BET bromodomain inhibitor combinations in breast cancer
Kornelia Polyak · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2030 · program · P50
Project 2: Rational approaches to improve treatment outcomes of patients with breast cancer brain metastases
Nancy U Lin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2025 · program · P50
Developmental Research Program
Nikhil Wagle · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2025 · program · P50
Project 1 - Overcoming Breast Cancer Resistance to CDK4/6 Inhibition
Eric P Winer · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2025 · program · P50
Career Enhancement Program
Judy E. Garber · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2020 · program · P01
Molecular Characterization of Myelin-Specific T cells from MS Patients
Vijay K. Kuchroo · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2030 · program · P50
Administration, Advocacy, Planning and Communication Core
Kornelia Polyak · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2025 · program · P50
Core A: Administrative
Kornelia Polyak · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2030 · program · P50
Core B: Biostatistics and Computational Biology Core
Nabihah Tayob · Dana-Farber Cancer Institute · funded by National Institutes of Health
2013–2020 · program · P01
Novel Technologies for Investigation of Self-reactive T cells in MS and Relevant
Vijay K. Kuchroo · Dana-Farber Cancer Institute · funded by National Institutes of Health
2012–2023 · research · R01
Targeting DOT1L for Degradation in MLL-rearranged Leukemia
Scott A Armstrong · Dana-Farber Cancer Institute · funded by National Institutes of Health
2012–2023 · research · R01
Targeting DOT1L for Degradation in MLL-rearranged Leukemia
Scott A Armstrong · Dana-Farber Cancer Institute · funded by National Institutes of Health
2012–2022 · research · R01
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer
Donald W. Kufe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2012–2022 · research · R01
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer
Donald W. Kufe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2012–2022 · research · R01
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer
Donald W. Kufe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2012–2023 · research · R01
Targeting DOT1L for Degradation in MLL-rearranged Leukemia
Scott A Armstrong · Dana-Farber Cancer Institute · funded by National Institutes of Health
2012–2023 · research · R01
Targeting DOT1L for Degradation in MLL-rearranged Leukemia
Scott A Armstrong · Dana-Farber Cancer Institute · funded by National Institutes of Health
2012–2023 · research · R01
Targeting DOT1L for Degradation in MLL-rearranged Leukemia
Scott A Armstrong · Dana-Farber Cancer Institute · funded by National Institutes of Health
